RBC Capital analyst Gregory Renza maintains Amgen (NASDAQ:AMGN) with a Outperform and lowers the price target from $360 to $330.
RBC Capital Maintains Outperform on Amgen, Lowers Price Target to $330
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.